Unexpected prolonged myelosuppression after mitomycin, mitoxantrone and methotrexate.
28 patients (26 with breast cancer and 2 with colon cancer) received mitomycin, mitoxantrone and methotrexate (MMM). Half the patients had grade III-IV leukopenia and 29% had grade III-IV thrombocytopenia. The median time of recovery to WHO grade 0 was 62 and 128 days, respectively. Thrombocytopenia and leukopenia were more frequent and longer lasting after the three-drug part of the therapy, which suggests a critical role for mitomycin in this toxicity.
Muhonen
T T
TT
Department of Radiotherapy and Oncology, Helsinki University Central Hospital, Finland.
Wiklund
T A
TA
Blomqvist
C P
CP
Pyrhönen
S O
SO
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D003110:Colonic Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced*; D008297:Male; D008727:Methotrexate / Q000009:adverse effects; D008875:Middle Aged; D008937:Mitomycins / Q000009:adverse effects; D008942:Mitoxantrone / Q000009:adverse effects; D013921:Thrombocytopenia / Q000139:chemically induced*; D013997:Time Factors
D008937:Mitomycins; D008942:Mitoxantrone; D008727:Methotrexate